Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy

NCT02134912 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT02134912
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02134912 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
S1300: A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-squamous NSCLC Patients Who Have Progressed Systemically After Previous Clinical Benefit From Crizotinib Monotherapy
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 2
Overall status
Terminated
Start date
August 31, 2014
Completion date
September 30, 2016
Enrollment
1 (actual)
Sites
167

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the lung, large cell lung cancer, recurrent non-small cell lung cancer, stage iv non-small cell lung cancer